Your browser doesn't support javascript.
Symptoms of Dry Eye Disease in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19).
Wang, Yan; Yang, Sen; Zhang, Yue; Zhang, Xin; Jiang, Yaping; Wang, Xixi; Zheng, Pengxiang; Chen, Yihui.
  • Wang Y; Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Yang S; Department of General Practice, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Zhang Y; Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
  • Zhang X; Department of Ophthalmology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Jiang Y; Department of Ophthalmology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Wang X; Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Zheng P; Department of Cardiology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Chen Y; Department of Ophthalmology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.
J Ophthalmol ; 2021: 2678706, 2021.
Article in English | MEDLINE | ID: covidwho-1559286
ABSTRACT

BACKGROUND:

We aimed to investigate the symptoms of the dry eye disease (DED) of hospitalized patients with coronavirus disease 2019 (COVID-19).

METHODS:

This cross-sectional, observational study analysis included 91 hospitalized patients with confirmed COVID-19 in Wuhan, China. The Ocular Surface Disease Index (OSDI) and the five-item Dry Eye Questionnaire (DEQ-5) were used to assess the severity of DED symptoms in the patients, and the analysis of variance was used to determine the factors associated with DED.

RESULTS:

A total of 42 patients consented to complete the investigation (response rate 46.15%). There were 26 (61.90%) patients who were diagnosed with DED symptoms by OSDI, and there were 28 (66.67%) patients with DED symptoms who were diagnosed by DEQ-5 score. For the biochemical tests, the patients with DED symptoms had lower aspartate aminotransferase (AST) levels compared to those with no DED symptoms (20.86 vs. 42.14, p=0.04). Further analysis showed that a previous history of cardiac or stroke disease (p=0.02) and typical symptoms of muscle soreness (p=0.03) were significantly different among the four DED symptoms groups on the basis of OSDI scores. The contributing factors of OSDI were mainly focused on visual function and environmental triggers.

CONCLUSION:

The incidence of DED symptoms is higher in hospitalized patients with COVID-19. The serum AST levels, history of cardiac or stroke disease, and the typical symptoms of muscle soreness may be the main impact factors on DED symptoms. We also need to pay more attention to the visual function and environmental triggers of hospitalized patients with COVID-19.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: J Ophthalmol Year: 2021 Document Type: Article Affiliation country: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: J Ophthalmol Year: 2021 Document Type: Article Affiliation country: 2021